Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Properly preparing Retatrutide for research use is a critical step in maintaining the peptides stability, accuracy, and potency
Please talk with your pharmacy directly about insurance coverage
Currently available treatment with proven outcomes Semaglutide FDA-approved for diabetes (Ozempic), obesity (Wegovy), and CV risk reduction with 7+ years of clinical and post-marketing data Cardiovascular risk reduction Semaglutide SELECT trial demonstrated 20% MACE reduction in 17,604 patients -- the first anti-obesity drug with proven cardiovascular benefit Maximum weight loss potential Retatrutide Phase 2 data showed 24.2% weight loss at 48 weeks with weight curves still declining, though Phase 3 confirmation is required Metabolic liver disease (MASLD/MASH) Retatrutide Glucagon receptor agonism directly promotes hepatic fat oxidation, a mechanistic advantage for liver-specific outcomes Oral administration preference Semaglutide Only incretin-class drug available as an oral tablet (Rybelsus), with higher-dose oral formulations under development Type 2 diabetes with established treatment guidelines Semaglutide Integrated into clinical guidelines with multiple approved doses and formulations, extensive comparative data, and guideline positioning Continue Your Research Get comparison updates We publish new head-to-head comparisons regularly
CagriSema: A Dual-Target Therapy for Obesity and Type 2 Diabetes Novo Nordisk unveiled the Phase 3 results from the REDEFINE 1 and REDEFINE 2 studies of CagriSema, a fixed-dose combination of cagrilintide (an amylin analog) and semaglutide
Utilizing a unique Triple-Pathway delivery system, this medication works by concurrently activating the Glucagon-like peptide-1 (GLP-1), Glucose-dependent insulinotropic polypeptide (GIP), and Glucagon (GCG) receptors
In newly diagnosed type 2 diabetic patients, a 3-month trial showed significant reductions in hemoglobin A1c (HbA1c), fasting blood glucose, and postprandial glucose levels, comparable to metformin
US$ 20.71
US$ 20.46
US$ 29.49
